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A B S T R A C T
Purpose
To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation
cyclophosphamide–based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation
with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-
matched unrelated donor (MUD).
Patients and Methods
We retrospectively evaluated 709 adult patients with Hodgkin lymphomawhowere registered in the
European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98),
SIB (n = 338), or MUD (n = 273) transplantation.
Results
Median follow-up of survivors was 29 months. No differences were observed between groups in
the incidence of acute graft-versus-host disease (GVHD). HAPLOwas associated with a lower risk
of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse
mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and cor-
responding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%,
respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO
(P = .26) and higher in MUD (P = .003), and risk of relapse was lower in both HAPLO (P = .047) and
MUD (P , .001). Two-year overall survival and progression-free survival were 67% and 43% for
HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no sig-
niﬁcant differences in overall survival or progression-free survival between HAPLO and SIB or
MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival
was signiﬁcantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD
(38%; P = .59).
Conclusion
Post-transplantation cyclophosphamide–based HAPLO transplantation results in similar survival
outcomes compared with SIB and MUD, which conﬁrms its suitability when no conventional donor
is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD
transplantation.
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INTRODUCTION
The number of patients with Hodgkin lymphoma (HL) who are
treated with allogeneic hematopoietic cell transplantation (alloHCT)
has signiﬁcantly increased over the last decade.1,2 Several retrospective
studies and one prospective clinical trial have demonstrated that young
patients with chemosensitive disease can clearly beneﬁt from alloHCT
using reduced-intensity conditioning (RIC) regimens.3-9 According to
the current recommendations of the European Society for Blood and
Marrow Transplantation (EBMT), alloHCT is considered the standard
treatment option in eligible patients who experience sensitive
relapse after autologous hematopoietic cell transplantation and
with a sibling (SIB) or a matched unrelated (MUD) donor2;
however, there is a signiﬁcant proportion of patients for whom
a conventional donor is not available. To address this issue, other
options, such as HLA-haploidentical transplantation (HAPLO)
or cord blood transplantation, have been explored.
HAPLO transplantation with extensive in vivo or ex vivo T-cell
depletion that has been used to reduce the risk of severe graft-versus-
host disease (GVHD) was historically associated with poor out-
come, mainly because of a high risk of nonrelapse mortality
(NRM), disease relapse, and delayed immune reconstitution10,11;
however, encouraging results have been reported with HAPLO
after a nonmyeloablative regimen and post-transplantation cy-
clophosphamide (PTCy) as GVHD prophylaxis.12-18 Three recent
registry studies (two from the Center for International Blood and
Marrow Transplant Research and another from EBMT, including
patients with lymphoid malignancies) suggest similar survival
outcomes with lower incidence of chronic GVHD for HAPLO
using PTCy compared with SIB and MUD transplantations.18-20
NRM, disease relapse, survival, and GVHD incidence have
been historically recognized as the main single end points with
which to evaluate the effectiveness of novel alloHCT strategies;
however, as a result of the complexity of the alloHCT procedure
in which decreases in NRM and GVHD often come at the cost of
increased relapse, no one factor is sufﬁcient when examining
post-transplantation outcomes. Recently, novel composite end
points that encompass not only mortality and relapse, but other
clinically meaningful post-transplant events, such as GVHD, are
being increasingly used to quantify survival without signiﬁcant
morbidity after alloHCT.21-24 GVHD-free/relapse-free survival
(GRFS) has developed as a novel composite end point that may
be more indicative of clinical success when comparing tradi-
tional alloHCT procedures with new platforms, such as HAPLO
using PTCy.
The objective of the current study was to compare the out-
comes of alloHCT, including GRFS, using HAPLO donors with the
PTCy approach with the outcomes of conventional HLA-identical
SIB donors and MUD donors for patients with HL.
PATIENTS AND METHODS
Data Source
EBMT is a voluntary organization that comprises more than 500
transplant centers, mainly from Europe. Accreditation as a member
center requires submission of the minimal essential data form A from all
consecutive patients to a central registry from which patients can be
identiﬁed by diagnosis of underlying disease and type of transplantation.
Minimal essential data form A data are annually updated. Informed
consent for transplantation and data collectionwas obtained locally according
to regulations that were applicable at the time of transplantation. Since
January 1, 2003, all transplantation centers have been required to obtain
written informed consent before data registration with the EBMT in
accordance with the 1975 Helsinki Declaration.
Patient Eligibility
Eligible patients were age$ 18 years and had undergone alloHCT for
HL between January 2010 and December 2013. Transplantations from
mismatched related donors—two or more mismatches—were identiﬁed as
haploidentical transplantations. Baseline information and transplantation
characteristics of eligible patients were downloaded and centers were
contacted to provide additional information about post-transplant out-
comes. Outcomes of patients who received PTCy-based HAPLOwas compared
with those of patients who were identiﬁed in the EBMT database as having
received transplantation from a matched SIB donor or MUD (matched at
the allele-level at HLA-A, -B, -C, and -DRB1) but otherwise meeting the
eligibility criteria described above. Patients who received ex vivo graft
manipulation were not eligible.
Statistical Analysis
Patient characteristics were compared by using a Kruskall-Wallis test
for quantitative variables, and x2 or Fisher’s exact test for categorical
variables. NRM was deﬁned as the time from alloHCT to death in the
absence of prior relapse and/or progression. Relapse rate was calculated
as the time from alloHCT to relapse and/or progression. NRM and
relapse rate events were considered as competing risks. Chronic GVHD
(cGVHD) was also analyzed in a competing-risks setting, with death
and relapse as competing events. Progression-free survival (PFS) was
deﬁned as the time from alloHCT to relapse and/or progression or
death from any cause, and overall survival (OS) was deﬁned as the time
from alloHCT to death from any cause. A composite end point deﬁned
as extensive cGVHD-free, relapse-free survival (cGRFS) after trans-
plantation was also studied. This end point was calculated as the time
from alloHCT to relapse and/or progression, to the onset of extensive
cGVHD, or to death from any cause.
Probabilities of OS, PFS, and cGRFS were estimated by using the
Kaplan-Meier product limit method and compared by using the log-rank
test. Estimates of NRM, relapse rate, and cGVHD were calculated by
using cumulative incidence curves to accommodate competing risks, and
were compared by using Gray’s test. The effect of donor type on NRM,
relapse rate, PFS, and OS was assessed by multivariable analyses (Cox
proportional hazards regression models or competing risk proportional
subdistribution hazards regression models) adjusting by potential
prognostic factors. The effect of donor type was investigated by multi-
variable models, adjusting for time from HL diagnosis to alloHCT,
sex, age at transplantation, previous autologous hematopoietic cell
transplantation, disease status at transplantation, performance status at
transplantation, type of conditioning regimen, patient and donor cy-
tomegalovirus status, and donor sex. Several models were constructed that
explored different cutoff values for continuous variables or classifying
disease status in different groups or in two categories (sensitive v re-
fractory disease). The proportionality assumption was tested for each
covariate factor. All variables met the proportionality assumption. A
backward stepwise method was used that included the type of donor as
the main factor-of-interest in all steps of model building. Survival and
cumulative incidence results are presented as estimates and 95% CIs.
Association of factors with end points is presented as relative risk (RR)
and 95% CI. All tests were two-sided and P values, .05 were considered
as indicating signiﬁcant associations. Analyses were performed by using
the SPSS for Windows version 20.0 (SPSS, Chicago, IL) and R Project
software, version 2.15.2.
3426 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Martı´nez et al
Downloaded from ascopubs.org by UCL Library Services on December 19, 2017 from 128.041.035.146
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
RESULTS
Baseline Characteristics
Baseline patient-, disease- and transplantation-related char-
acteristics are listed in Table 1. A signiﬁcantly higher number of
patients in the HAPLO group received RIC regimens, bonemarrow
stem-cells (BMSC), and had female donors. Patients in the SIB and
MUD groups received calcineurin inhibitor–based prophylaxis
plus antithymocyte globulin (ATG; 14% and 51%, respectively) or
campath (23% and 23%, respectively).
Hematopoietic Recovery
The cumulative incidence of neutrophil recovery at day 28 for
patients who received BMSC was 96% (95% CI, 91 to 100) in the
HAPLO group compared with 94% (95% CI, 86 to 100) and 93%
(95% CI, 84 to 100) in the SIB and MUD groups, respectively
(P = .82). The day 28 cumulative incidence of platelet recovery in
similar order was 67% (95% CI, 48 to 92), 87% (95% CI, 75 to
100), and 79% (95% CI, 63 to 99) (P = .79). For peripheral blood
stem-cell (PBSC) transplantations, the cumulative incidence of
neutrophil recovery was 97% (95% CI, 92 to 100) in the HAPLO
group compared with 96% (95% CI, 94 to 98) and 94% (95% CI,
91 to 97) in the SIB and MUD groups, respectively (P = .02). The
cumulative incidence of platelet recovery in similar order was 72%
(95% CI, 54 to 96), 90% (95% CI, 85 to 95), and 89% (95% CI, 84
to 95; P = .01). Engraftment results expressed as median time and
ranges to recovery are provided in the Appendix (online only).
Acute and cGVHD
The rate of grade II to IV acute GVHD after HAPLO was
higher compared with that of SIB (33% v 18%; P = .003),
whereas no differences were observed in comparison with MUD
(30%; P = .36). The incidence of grade III to IVacute GVHD was
similar between the three groups (HAPLO, 9%; SIB, 6%; and
MUD, 9%; P = .54). The cumulative incidence of cGVHD at 1
year after HAPLO, SIB, and MUD was 26% (95% CI, 18 to 39),
25% (95% CI, 20 to 32), and 41% (95% CI, 34 to 48), re-
spectively (P = .017). In univariable analysis, MUD was asso-
ciated with a higher risk of cGVHD compared with SIB
(P = .012) and HAPLO (P = .04; Table 2 and Fig 1). Results were
Table 1. Characteristics of Patients and alloHCT According to the Type of Donor
Characteristic
HAPLO
(n = 98)
SIB
(n = 338)
MUD
(n = 273) P
Median age at alloHCT, years (range) 31 (18-68) 32 (18-67) 32 (18-68) .37
Sex, No. (%) .18
Male 56 (57) 193 (57) 175 (64)
Female 42 (43) 145 (43) 98 (36)
Performance status, No. (%) .84
Good (. 80% KS) 81 (95) 301 (95) 240 (96)
Poor (, 80% KS) 4 (5) 16 (5) 10 (4)
HL status, No. (%) .1
Chemosensitive 83 (85) 264 (78) 230 (84)
Refractory 15 (15) 74 (22) 43 (16)
Yes for previous autoHCT, No. (%) 75 (77) 236 (70) 206 (76) .2
Median time from HL diagnosis to alloHCT, months (range) 30 (11-179) 28 (6-343) 35 (3-269) .01
Source of stem cells, No. (%) , .001
Bone marrow 60 (61) 33 (10) 31 (11)
Peripheral blood 38 (39) 302 (89) 241 (88)
Female donor, No. (%) 54 (55) 152 (45) 61 (23) , .001
Reduced intensity conditioning regimen, No. (%) 84 (90) 218 (69) 172 (69) , .001
TBI in conditioning, No. (%) 61 (62) 42 (13) 28 (10) , .001
Conditioning regimen, No. (%) , .001
Flu +Cy + 2 Gy TBI 57 (58) 4 (1) 3 (1)
Flu +Cy + Bu 22 (22) 1 (0.3) 0
Flu + Mel 2 (2) 112 (33) 82 (30)
Flu + Bu 2 (2) 51 (15) 41 (15)
Other Flu-based regimen 10 (10) 88 (26) 73 (27)
BEAM 0 36 (11) 28 (10)
Cy +TBI or Bu 1 (1) 20 (6) 9 (3)
Other 4 (4) 26 (8) 37 (13)
GVHD prophylaxis, No. (%) , .001
Post-transplantation Cy 98 (100) — —
CNI + MTX 6 others 2 (2) 132 (39) 90 (33)
CNI + MMF 6 others (except MTX) 92 (94) 90 (27) 90 (34)
CNI 6 others (except MTX/MMF) 0 88 (26) 64 (23)
ATG as part of GVHD proﬁlaxis 0 48 (14) 139 (51)
Campath as part of GVHD proﬁlaxis 0 79 (23) 64 (23)
Abbreviations: alloHCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocyte globuline; autoHCT, autologous hematopoietic stem cell trans-
plantation; BEAM, carmustine, etoposide, arabinoside of cytosine, melphalan; Bu, busulfan; CNI, calcineurine inhibitors; Cy, cyclophosphamide; Flu, ﬂudarabine; GVHD,
graft-versus-host disease; HAPLO, haploidentical donor; HL, Hodgkin lymphoma; KS, Karnofsky status; Mel, melphalan; MMF, mofetil mycophenolate; MTX, meth-
otrexate; MUD, match-unrelated donor; SIB, sibling donor; TBI, total-body irradiation.
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similar when we analyzed the cumulative incidence of cGVHD
according to BMSC or PBSC.
NRM and Relapse
One hundred twenty-nine (18%) patients died without ex-
periencing disease relapse and/or progression. No differences in the
cumulative incidence of NRM at 1 year were observed between
HAPLO and SIB (17% v 13%; P = .37), whereas MUD had
a signiﬁcantly higher NRM compared with SIB (21% v 13%;
P = .006; Table 2 and Fig 2A). In multivariable analysis, the
variables associated with a higher NRMwere MUD (RR, 1.78; 95%
CI, 1.21 to 2.60; P = .003), age $ 40 years (RR, 1.78; 95% CI, 1.24
to 2.55; P = .002), poor performance status (RR, 2.39; 95% CI, 1.22
to 1.68; P = .011), and refractory HL (RR, 1.62; 95% CI, 1.05 to
2.50; P = .03; Table 3).
A total of 280 (39%) patients experienced relapse. The cu-
mulative incidence of disease progression and/or relapse at 2 years
was 39% (95% CI, 30 to 51), 49% (95% CI, 43 to 55), and 32%
(95% CI, 26 to 38) after HAPLO, SIB, and MUD, respectively (Fig
2B). In multivariable analysis, SIB was associated with a higher
relapse risk compared with MUD (RR, 0.57; 95% CI, 0.43 to 0.74;
P , .001) and HAPLO (RR, 0.69; 95% CI, 0.48 to 0.99; P = .047;
Table 3). Other factors associated with a higher relapse rate were
male gender (RR, 1.28; 95% CI, 1.01 to 1.63; P = .049), poor
performance status (RR, 1.88; 95% CI, 1.1 to 3.2; P = .02), and
refractory HL (RR, 2.67; 95% CI, 2.04 to 3.48; P , .001; Table 3).
Survival
Four hundred forty-eight (63%) of 709 patients are currently
alive, with a median follow-up for surviving patients of 27 months
(range, 1.1 to 64 months) for HAPLO, 27 months (range, 1 to
76 months) for SIB, and 31 months (range, 0.9 to 70 months)
for MUD. The 2-year OS was not signiﬁcantly different between
HAPLO (67%; 95% CI, 57 to 76) and SIB (71%; 95% CI, 66 to
Table 2. Univariable Analysis for Survival Outcomes, Nonrelapse Mortality, and Relapse by Donor Type
Outcomes HAPLO (n = 98) SIB (n = 338) MUD (n = 273) P
NRM .023
1-year cumulative incidence 17% 13% 21% HAPLO v SIB, .37
95% CI 11 to 27 10 to 17 16 to 26 HAPLO v MUD, .30
SIB v MUD, .006
Relapse rate , .001
2-year cumulative incidence 39% 49% 32% HAPLO v SIB, .039
95% CI 30 to 51 43 to 55 26 to 38 HAPLO v MUD, .31
SIB v MUD, , .001
PFS .086
2-year cumulative incidence 43% 38% 45% HAPLO v SIB, .18
95% CI 33 to 54 31 to 43 39 to 51 HAPLO v MUD, .91
SIB v MUD, .038
OS .118
2-year cumulative incidence 67% 71% 62% HAPLO v SIB, .51
95% CI 57 to 76 66 to 76 56 to 68 HAPLO v MUD, .44
SIB v MUD, .039
Chronic GVHD .017
1-year cumulative incidence 26% 25% 41% HAPLO v SIB, .90
95% CI 18 to 39 20 to 32 34 to 49 HAPLO v MUD, .040
SIB v MUD, .012
Extensive cGVHD and PFS .04
2-year cumulative incidence 40% 28% 38% HAPLO v SIB, .049
95% CI 29 to 51 23 to 34 32 to 44 HAPLO v MUD, .59
SIB v MUD, .038
Abbreviations: cGVHD, chronic graft-versus-host disease; HAPLO, haploidentical donor; MUD, match-unrelated donor; NRM, nonrelapse mortality; OS, overall survival;
PFS, progression-free survival; SIB, sibling donor.
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76; P = .51), whereas patients who underwent MUD trans-
plantation had a lower OS (62%; 95% CI, 56 to 68; P = .039)
than those who received an SIB alloHCT (Fig 2C). These results
were conﬁrmed in multivariable analysis (Table 3). Other
predictors for a worse OS were age$ 40 years (RR, 1.62; 95% CI,
1.25 to 2.11; P , .001), poor performance status (RR, 2.4; 95%
CI, 1.51 to 3.83; P, .001), and refractory HL (RR, 2.15; 95% CI,
1.62 to 2.85; P , .001; Table 3).
The 2-year PFS was similar between HAPLO and SIB
(43%; 95% CI, 33 to 54; and 38%; 95% CI, 31 to 43, re-
spectively; P .18), but signiﬁcantly better after MUD (45%;
95% CI, 39 to 51; P = .038) than after an SIB alloHCT (Fig 2D).
Multivariable analysis did not demonstrate signiﬁcant dif-
ferences in PFS after HAPLO or MUD in relation to SIB
(Table 3). Factors associated with a worse PFS were age $ 40
years (RR, 1.31; 95% CI, 1.06 to 1.63; P = .014), poor per-
formance status (RR, 2.05; 95% CI, 1.35 to 3.11; P = .001), and
refractory HL (RR, 2.22; 95% CI, 1.76 to 2.79; P , .001). The
rate of the composite end point of 2-year cGRFS was signif-
icantly better for HAPLO (40%; 95% CI, 29 to 51) compared
with SIB (28%; 95% CI, 23 to 34; P = .049) and similar to MUD
(38%; 95% CI, 32 to 44; P = .59; Fig 2E).
A multivariable subanalysis that included HAPLO, SIB,
MUD with ATG, and MUD without ATG indicated that HAPLO
was associated with a lower relapse rate than SIB (hazard ratio,
0.69; 95% CI, 0.48 to 1.0; P = .047) with no signiﬁcant dif-
ferences in NRM, OS, or PFS. No differences were observed
between HAPLO and MUD with or without ATG (Appendix
and Appendix Table A1, online only). These results were in line
with the outcomes shown in the main analysis.
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Fig 2. (A) Cumulative incidence of nonrelapse mortality (NRM) in recipients of sibling donor (SIB), match-unrelated donor (MUD), and haploidentical donor
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DISCUSSION
Here, we describe the largest series of patients with HL who
underwent HAPLO alloHCT that used PTCy-based GVHD prophylaxis
compared with transplantations that used either a MUD or an
SIB donor. This registry analysis demonstrates that the survival
outcomes of HAPLO transplantation are comparable with that of
conventional SIB and MUD transplantations across multiple
centers and conditioning regimens. Moreover, HAPLO alloHCT
seems to be associated with signiﬁcantly lower rates of cGVHD
compared with MUD transplantations.
Thus far, there is only one nonrandomized study that com-
pared HAPLO transplantations with SIB andMUD in patients with
HL.25 In that retrospective study by Burroughs et al, 90 patients
with HL were treated with a nonmyeloablative conditioning reg-
imen followed by alloHCT from an SIB (n = 38), anMUD (n = 24),
or a HAPLO (n = 28) donor. HAPLO transplantation was per-
formed by using unmanipulated bone marrow as a graft source and
PTCy as GVHD prophylaxis. The authors did not ﬁnd signiﬁcant
differences in OS among the three groups; however, signiﬁcantly
improved PFS was observed for HAPLO compared with SIB and
MUD. NRM and relapse were lowest among HAPLO recipients. In
our study, HAPLO compares favorably with SIB in terms of relapse
rate and without differences in OS. In contrast to this series, we
found no signiﬁcant differences in post-transplantation out-
comes between HAPLO and MUD, except for a lower incidence
of cGVHD for HAPLO transplantation. It should be noted that
in the study by Burroughs et al, NRM reported after MUD
transplantation was unexpectedly low (8%). We found a 2-year NRM
of 13% and 23% after SIB and MUD alloHCT, respectively, which are
in line with previous nonrandomized studies that compared SIB and
MUD transplantations in patients withHL.3,5,26,27 In the current study,
2-year OS (71% and 62% after SIB andMUD, respectively) and 2-year
PFS (38% and 45% after SIB and MUD, respectively) also compare
similarly with those reported by other groups.3,5,21,26-28
Recently, two retrospective studies from the Center for In-
ternational Blood and Marrow Transplant Research compared
outcomes after HAPLO with MUD and SIB transplantations.18,19
Only 22% of patients who were included in these large series had
HL. Both studies—the ﬁrst comparing HAPLO with MUD with
and without ATG, and the second comparing HAPLO with
SIB—reported similar survival outcomes with a lower risk of
cGVHD for those patients who received HAPLO.
In the current study, no differences between groups in the
incidence of acute grade II to IV GVHD were observed; however,
the 1-year cumulative incidence of cGVHD was higher for MUD
(41%) compared with SIB (25%; P = .012) and HAPLO (26%;
P = .04). The lower cGVHD rate with HAPLO is in line with recent
reports in patients with lymphoma and acute myeloid leukemia.
The incidence of acute and cGVHD in our study seems to be lower
for all groups than that reported by Burroughs et al25 despite the
fact that most patients in our study received PBSC. This could be
explained by the use of ATG or alemtuzumab in a signiﬁcant
proportion of patients in the SIB (14% and 23%, respectively) and
MUD (51% and 23%, respectively) groups. In our study, the low
incidence of cGVHD after HAPLO resulted in a lower rate of
cGFRS at 2 years (40%) compared with SIB (28%; P = .049) and
similar to MUD (38%; P = .59).
In support of the role of HAPLO for the treatment of relapsed
HL, three recently published series report encouraging results.28-30
In a retrospective study, Raiola et al28 reproduced the Burroughs et al
data, which conﬁrmed the reproducibility of the PTCy HAPLO
Table 3. Multivariable Cox Proportional Hazards Models With Donor Type as
a Covariate
Factor HR 95% CI P
Cox model on NRM
Donor type
SIB
MUD 1.78 1.21 to 2.60 .003
HAPLO 1.38 0.79 to 2.39 .26
Age, years
# 39
$ 40 1.78 1.24 to 2.55 .002
Performance status
Good
Poor 2.39 1.22 to 4.68 .011
Refractory HL
Nonrefractory
Refractory 1.62 1.05 to 2.50 .03
Cox model on relapse rate
Donor type
SIB
MUD 0.57 0.43 to 0.74 , .001
HAPLO 0.69 0.48 to 0.99 .047
Sex
Female
Male 1.28 1.01 to 1.63 .049
Performance status
Good
Poor 1.88 1.1 to 3.2 .02
Refractory HL
Nonrefractory
Refractory 2.67 2.04 to 3.48 , .001
Cox model on OS
Donor type
SIB
MUD 1.47 1.13 to 1.92 .004
HAPLO 1.24 0.84 to 1.82 .27
Age, years
# 39
$ 40 1.62 1.25 to 2.11 , .001
Performance status
Good
Poor 2.4 1.51 to 3.83 , .001
Refractory HL
Nonrefractory
Refractory 2.15 1.62 to 2.85 , .001
Cox model on PFS
Donor type
SIB
MUD 0.86 0.69 to 1.06 .17
HAPLO 0.82 0.61 to 1.12 .22
Age, years
# 39
$ 40 1.31 1.06 to 1.63 .014
Performance status
Good
Poor 2.05 1.35 to 3.11 .001
Refractory HL
Nonrefractory
Refractory 2.22 1.76 to 2.79 , .001
Abbreviations: HAPLO, haploidentical donor; HL, Hodgkin lymphoma; HR,
hazard ratio; MUD, match-unrelated donor; NRM, nonrelapse mortality; OS,
overall survival; PFS, progression-free survival; SIB, sibling donor.
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procedure in terms of toxicity and efﬁcacy. In this series, the
cumulative incidence of NRM was low (4%) and the relapse rate
(31%) was the major cause of treatment failure. Three-year OS and
PFS were 77% and 63%, respectively, in this small series of 26
patients. Gayoso et al29 reported a series of 43 patients who received
HAPLO with an RIC approach that substituted total-body irra-
diation with busulfan in the conditioning regimen in an attempt to
reduce the relapse rate. In contrast to the study by Raiola et al, most
patients received PBSC graft instead of BMSC. NRM at 1 year
(21%) was similar to that observed in our study (17%) and higher
than that previously reported, likely as a result of the use of more
intensive conditioning regimens.21,25 Relapse was also the main
problem in this series, with a cumulative incidence of 24% at
2 years. Estimated 2-year PFS and OS were 48% and 58%, re-
spectively, and these results compare similarly with our experience.
Finally, Castagna et al30 have recently reported similar results
(3-year OS, 63%; and PFS, 59%) in a series of 62 patients with HL.
This study has some inherent limitations as with other
registry-based analyses. The decision to perform an MUD versus
a HAPLO transplantation was not an intent-to-treat one; a shorter
time from diagnosis to alloHCT for the HAPLO group may suggest
that some patients have been offered HAPLO on the basis of
institutional preferences, but it may also indicate a shorter time to
make the necessary arrangements to perform HAPLO trans-
plantation compared with MUD. Second, the nature of the data
captured by the registry does not allow us to evaluate the effect of
different types of conditioning regimens on transplant outcome.
Thus, although a signiﬁcantly higher proportion of HAPLO trans-
plantations were performed using RIC regimens compared with SIB
and MUD, recent data indicate that, at least for those alloHCTs
performed more recently, outcomes after transplantation are
similar after myeloablative conditioning regimens and RIC.31
Finally, differences in GVHD prophylaxis approaches be-
tween SIB and MUD, and the use of BMSC for most HAPLO
transplantations versus PBSC for most SIB and MUD trans-
plantations, prevents us from being able to segregate the effect of
donor versus GVHD prophylaxis and type of graft source.
Nevertheless, this is the largest reported series that compared
HAPLO, SIB, and MUD in HL; all HAPLO transplantations were
performed by using PTCy as GVHD prophylaxis; and median
follow-up for HAPLO transplantations was similar to SIB and
MUD.
In the absence of randomized data, our study suggests that
PTCy-based HAPLO alloHCT is associated with comparable re-
sults with respect to NRM, OS, and PFS with those of conventional
transplantations. Moreover, our results indicate that HAPLO re-
sults in a lower incidence of extensive cGVHD compared with
MUD transplantations and higher cGFRS compared with SIB.
Despite the lower cGVHD incidence in the HAPLO group, the risk
of relapse was lower than that in the SIB group and similar to that
for MUD transplantation group, which suggests that the graft-
versus-lymphoma effect in the HAPLO setting might be in-
dependent of a clinically signiﬁcant cGVHD. These results support
the use of HAPLO as an alternative for patients with advanced HL
who lack an SIB donor. Use of HAPLO donors may allow patients
to proceed more rapidly to transplantation, avoiding the time
needed to complete a formal MUD search and arrange for graft
collection at a remote center. Whether HAPLO transplantation is
the ﬁrst choice instead of MUD transplantation and whether it can
eventually substitute SIB transplantation in speciﬁc subgroups of
patients must be assessed within the context of a randomized
prospective clinical trial.
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Appendix
Hematopoietic Recovery
Median time to an absolute neutrophil count of$ 500/mm3 for patients who received bone marrow stem-cells was 18 days for
haploidentical (HAPLO), 20 days for sibling (SIB), and 20 days for HLA-matched unrelated donor (MUD; P = .23) transplantation.
Platelet recovery was not signiﬁcantly different among groups (median time to a platelet count of $ 20,000/mm3 was 20, 18, and
16 days for HAPLO, SIB, and MUD, respectively; P = .45). For those patients who received peripheral blood stem-cell trans-
plantation, median time for absolute neutrophil count of $ 500/mm3 was 18, 14, and 14 days for HAPLO, SIB, and MUD,
respectively (P, .001). Platelet recovery was signiﬁcantly faster for SIB andMUD recipients compared with patients in the HAPLO
group (13 and 12 days v 25 days, respectively; P , .001).
Effect of Antithymocyte Globulin or Campath Use on SIB and MUD alloHCT Outcomes
Because there was a tight correlation between donor type and the type of graft-versus-host-disease prophylaxis, we performed
a subset analysis of allogeneic hematopoietic cell transplantation (alloHCT) outcomes to assess the potential effect of antithymocyte
globulin (ATG) or campath on SIB andMUD alloHCToutcomes. Two separate multivariable analyses were performed, one that was
restricted to SIB with and without ATG or campath and another restricted to MUD with and without ATG or campath. Use of ATG
or campath did not have any effect on nonrelapse mortality (NRM), relapse, overall survival (OS), or progression-free survival
(PFS) in the SIB setting. Whereas the use of campath did not have any effect on alloHCToutcomes in the MUD group, use of ATG
was associated with a lower PFS (hazard ratio, 1.51; 95% CI, 1.1 to 2.1; P = .02), with no differences in the risk of NRM, relapse, and
OS. A subsequent multivariable analysis that included HAPLO, SIB, MUD with ATG, and MUD without ATG indicated that
HAPLO was associated with a lower relapse rate than SIB (hazard ratio, 0.69; 95% CI, 0.48 to 1.0; P = .047) with no signiﬁcant
differences in NRM, OS, or PFS (Appendix Table A1). No differences were observed between HAPLO and MUD with or without
ATG. These results were in line with the outcomes shown in the main analysis.
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Table A1. Multivariable Cox Proportional Hazards Models With Donor Type as
a Covariate: Analysis of Four Groups (HAPLO, SIB, MUD with ATG, and MUD
without ATG)
Factor HR 95% CI P
Cox model on NRM
Donor type
SIB
HAPLO 1.38 0.79 to 2.39 .25
MUD with ATG 2.31 1.50 to 3.54 , .001
MUD without ATG 1.31 0.81 to 2.12 .28
Age, years
# 39
$ 40 1.83 1.28 to 2.63 , .001
Performance status
Good
Poor 2.39 1.22 to 4.68 .011
Refractory HL
Nonrefractory
Refractory 1.60 1.03 to 2.47 .037
Cox model on relapse rate
Donor type
SIB
HAPLO 0.69 0.48 to 1.0 .047
MUD with ATG 0.67 0.48 to 0.94 .019
MUD without ATG 0.48 0.34 to 0.68 , .001
Sex
Female
Male 1.28 1.01 to 1.64 .045
Performance status
Good
Poor 1.84 1.08 to 3.13 .026
Refractory HL
Nonrefractory
Refractory 2.68 2.98 to 6.37 , .001
Cox model on OS
Donor type
SIB
HAPLO 1.27 0.86 to 1.86 .22
MUD with ATG 1.71 1.25 to 2.36 .001
MUD without ATG 1.27 0.91 to 1.78 .16
Age, years
# 39
$ 40 1.58 1.22 to 2.06 .001
Performance status
Good
Poor 2.37 1.48 to 3.80 , .001
Refractory HL
Nonrefractory
Refractory 2.13 1.61 to 2.83 , .001
Cox model on PFS
Donor type
SIB
HAPLO 0.87 0.64 to 1.17 .36
MUD with ATG 1.03 0.80 to 1.33 .80
MUD without ATG 0.67 0.51 to 0.89 .005
Age, years
# 39
$ 40 1.29 1.04 to 1.60 .021
Performance status
Good
Poor 2.0 1.32 to 3.03 .001
Refractory HL
Nonrefractory
Refractory 2.22 1.76 to 2.80 , .001
Abbreviations: ATG, antithymocyte globulin; HAPLO, haploidentical donor; HL,
Hodgkin lymphoma; HR, hazard ratio; MUD, match-unrelated donor; NRM,
nonrelapse mortality; OS, overall survival; PFS, progression-free survival; SIB,
sibling donor.
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